Observational analysis reveals that CSF total tau correlates stronger with synaptic biomarkers than neurodegeneration ones, suggesting its role as a key Alzheimer's disease indicator.
Key Points
CSF total tau shows a stronger correlation with synaptic degeneration markers than with neurodegeneration markers.
In cognitively unimpaired and impaired cohorts, synaptic biomarkers account for more variance in CSF total tau levels.
Elevated CSF total tau is found only in individuals with synaptic biomarker abnormalities, not neurodegeneration markers.
These findings indicate that CSF total tau may be a better proxy for synaptic degeneration in Alzheimer's disease.